
HSCS Stock Forecast & Price Target
HSCS Analyst Ratings
Bulls say
HeartSciences Inc is experiencing a positive financial trajectory, as evidenced by upward adjustments to its fiscal year 2026 earnings per share (EPS) estimates, suggesting improved operational performance amidst a growing share count. The anticipated approval of the MyoVista device, along with the rollout of the MyoVista Insights cloud platform and expected FDA approval for its first diagnostic algorithm in the first half of 2026, positions the company strategically for significant expansion in the cardiac diagnostic market. Furthermore, the new price target of $9.20 indicates a robust upside potential, reflecting a favorable net present value analysis that underscores HeartSciences's promising growth prospects.
Bears say
HeartSciences Inc. is currently facing significant challenges that contribute to a negative outlook on its stock, particularly highlighted by a drastic reduction in the FY2026 revenue estimate from $1.2 million to $0.1 million due to FDA-related delays. Additionally, the company is exposed to multiple risks, including balance sheet and liquidity concerns, potential failures in clinical trials, difficulties in gaining regulatory approvals, and competition within the healthcare sector. Overall, these factors, compounded by shifts in investor sentiment and healthcare priorities, significantly impact the company's financial outlook and operational viability.
This aggregate rating is based on analysts' research of Heart Test Laboratories Inc and is not a guaranteed prediction by Public.com or investment advice.
HSCS Analyst Forecast & Price Prediction
Start investing in HSCS
Order type
Buy in
Order amount
Est. shares
0 shares